- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Hypolipidemic agent, violates the early stages of the synthesis of cholesterol in the liver (at the stage of levanic acid).
It forms free beta-hydroxy acid in the body, which competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A-reductase (HMG-CoA-reductase) and disrupts its conversion to mevalonate, resulting in decreased cholesterol synthesis, and its catabolism is enhanced.
Reduces blood levels of very low density lipoproteins, low density lipoproteins and triglycerides, moderately increases the content of high density lipoproteins.
Significantly reduces the amount of apoprotein B (which is part of low density lipoproteins) and other circulating components of low density lipoproteins.
A pronounced therapeutic effect is manifested within 2 weeks, and the maximum - after 4-6 weeks from the start of treatment.
No customer reviews for the moment.